Table 6.
Base-case analysis
| Discounted valuea (undiscounted value) | Base-case analysis | Incremental analysis | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Drug costs (£) | Admin costs (£) | Monitoring costs (£) | AE costs (£) | Total costs (£) | QALYs | Inc. costs (£) | Inc. QALYs | ICER (£) | |
| DFP (Ferriprox®) | 25,775 | 0 | 1,231 | 186 | 27,191 | 3.918 | |||
| (27,577) | (0) | (1,317) | (199) | (29,093) | (4.192) | ||||
| DFO (Generic) | 25,602 | 44,429 | 2,411 | 0 | 72,442 | 3.006 | 45,251 | −0.912 | Dominated |
| (27,374) | (47,505) | (2,578) | (0) | (77,457) | (3.213) | (48,364) | (−0.979) | Dominated | |
| Combination therapy | 46,636 | 36,203 | 3,622 | 186 | 86,647 | 3.246 | 14,205 | 0.240 | 59,093 |
| (49,898) | (38,736) | (3,875) | (199) | (92,708) | (3.473) | (15,251) | (0.260) | (58,664) | |
| DFX (Exjade®) | 106,272 | 0 | 1,071 | 19 | 107,363 | 3.819 | 20,716 | 0.573 | 36,141 |
| (113,629) | (0) | (1,145) | (20) | (114,795) | (4.083) | (22,087) | (0.610) | (36,224) | |
aCosts and QALYs are discounted at a rate of 3.5 %, in line with UK Treasury guidelines
AE adverse events, DFO desferrioxamine, DFP deferiprone, DFX deferasirox, ICER incremental cost-effectiveness ratio, Inc. incremental, QALY quality-adjusted life year